Highlights for April 2017
- Capital International buys 3% stake in India based Intas Pharmaceuticals for $107 million
- Serum Institute of India acquires Czech Republic's Nanotherapeutics
- Sayre Therapeutics enters into agreement with Spanish company GP Pharm
- CRISPR Therapeutics and Casebia Therapeutics Announce Exclusive Development and Option Agreement with StrideBio
- Microbiome biotech Finch Therapeutics signs pact with Takeda to jointly work on FIN-524
- J&J is paying up to $1.15 billion to enlist PeptiDream to aim its peptide discovery platform at multiple cardiovascular and metabolic targets
- Astellas to buy GPCR specialist Ogeda for €500M upfront
- Bristol-Myers sells anti-tau, DMD assets to Biogen, Roche for $470M upfront, $615M in milestones
- Novartis signs collaboration deal with tiny Parvus for diabetes nanomedicine
- Fledgling biotech Vtesse in $200M buyout from Sucampo
- Nimbus in full-on drug development partnership with Charles River
For more such news and updates, please join our Group "Global Life Science Business Partnering" on LinkedIn.
Updates at Aagami:
- New Client Win for Aagami. UK based Client is has unique nanotechnology based delivery system that works with multiple forms such as topical, oral and injectable
- Aagami client JRF Global completes an action packed result focused trip to California. Both CEOs and also JRF BD Head North America were present
- Aagami registers for BIO International Convention June 19-22, 2017, in San Diego
- Aagami CEO to visit Japan, Korea, India in August 2017